New Delhi, August 25, 2026: India has introduced a set of regulatory changes aimed at making advanced medical devices available to patients faster by reducing approval-related hurdles, simplifying outsourced sterilisation requirements and bringing greater uniformity to testing fees.
The Union health ministry's reforms amend the Medical Devices Rules, 2017 in three major areas: recognition of the European Union as a stringent regulatory jurisdiction for certain clinical-investigation waivers, simplification of rules governing outsourced sterilisation, and standardisation of fees charged by medical-device testing laboratories.
The government says the changes are intended to reduce regulatory burden, improve predictability for manufacturers and importers, cut compliance costs and facilitate timely access to advanced and innovative medical technologies in India.
EU approvals could mean faster access in India
One of the most significant changes is the inclusion of the European Union among the recognised stringent regulatory jurisdictions under Rule 63 of the Medical Devices Rules.
Before this amendment, the provision recognised the United States, United Kingdom, Australia, Canada and Japan. The EU has now been added to that list.
The change is particularly important for medical devices that have already undergone regulatory scrutiny in Europe.
Under the amended framework, eligible devices approved in the EU can benefit from provisions that waive certain clinical-investigation requirements in India when there is no predicate device. This can potentially remove a major step in the Indian approval process and reduce the time required before a product can reach the market.
For patients, the practical implication could be quicker availability of newer technologies, particularly where a device has already been assessed by a major overseas regulatory system.
For manufacturers and importers, the move could reduce duplication in regulatory work. Instead of requiring every aspect of the approval process to be repeated in India, the framework can rely, in specified circumstances, on regulatory evidence generated in a recognised foreign jurisdiction.
The government has described this as part of a broader effort toward international regulatory convergence while maintaining standards for quality, safety and performance.
Why the change matters for patients
Medical devices cover a wide range of products, from relatively simple equipment to sophisticated technologies used for diagnosis, monitoring and treatment.
When regulatory procedures take longer, the introduction of newer products can also be delayed. This is particularly relevant for technologies that may provide doctors with additional treatment or diagnostic options.
By recognising EU regulatory approval within the specified waiver framework, India is attempting to shorten the path between international approval and domestic availability.
The change does not mean that every device approved in Europe will automatically be cleared for sale in India. The waiver applies to eligible medical devices under the relevant regulatory provisions. Manufacturers and importers will still have to meet applicable Indian requirements.
Outsourced sterilisation rules relaxed
The second major reform concerns sterilisation.
Sterilisation is a critical part of manufacturing many medical devices because products that enter or interact with the human body must meet appropriate safety and sterility requirements.
Previously, manufacturers that did not have their own sterilisation facility and instead used an external facility were required to obtain a separate loan licence for sterilisation activities.
The amended Rule 44 removes that requirement when the outsourced sterilisation facility itself holds a valid licence under the Medical Devices Rules, 2017.
This means manufacturers can use licensed specialised sterilisation providers without having to obtain an additional licence merely because the sterilisation process is being outsourced.
The government expects the change to reduce paperwork, compliance requirements, approval timelines and associated costs. It could also make it easier for manufacturers to access specialised sterilisation infrastructure rather than having to maintain such facilities themselves.
What is a loan licence?
A loan licence is essentially a regulatory mechanism that allows a manufacturer to undertake specified activities using the facilities or infrastructure of another licensed entity.
For companies that do not operate their own sterilisation facility, the earlier requirement created an additional regulatory step.
The revised provision shifts the focus toward the licensing status of the sterilisation facility itself. If that facility already has a valid licence under the Medical Devices Rules, the device manufacturer does not need a separate loan licence for the outsourced sterilisation activity.
The government believes this will make the system more efficient without removing the requirement that sterilisation facilities remain properly licensed.
Uniform testing fees introduced
The reforms also address the cost and transparency of medical-device testing.
The government has added a Ninth Schedule to the Medical Devices Rules, 2017 prescribing uniform fees for testing medical devices by recognised Medical Device Testing Laboratories.
Previously, variations in testing charges could create uncertainty for manufacturers and importers.
A standardised fee structure is intended to make costs more predictable. It can also reduce disputes and variations between laboratories while providing manufacturers with greater clarity when planning regulatory expenses.
The Health Ministry says the measure is designed to strengthen transparency, improve efficiency and ensure more consistent treatment of stakeholders.
Industry gets greater regulatory predictability
For medical-device companies, regulatory uncertainty can be almost as significant as the cost of compliance itself.
Manufacturers need to know how long approvals may take, what documentation will be required and how much testing will cost before committing resources to launching a product.
The new measures attempt to address each of these areas.
EU recognition could reduce clinical-investigation requirements for eligible devices. The sterilisation amendment removes an additional licensing requirement in specified outsourcing arrangements. And uniform testing fees provide greater clarity about laboratory costs.
Taken together, the government expects the changes to reduce compliance costs and make India's regulatory environment more predictable.
Faster access does not mean lower safety standards
An important aspect of the reforms is that the government has framed them as simplification rather than deregulation.
The Health Ministry has said the changes are intended to improve ease of doing business while continuing to ensure high standards of quality, safety and performance.
Recognising the EU as a stringent regulatory jurisdiction means that, for eligible products, India can take greater account of regulatory assessment already conducted in Europe. It does not eliminate India's overall medical-device regulatory framework.
Similarly, the sterilisation reform removes a licensing layer for manufacturers using an already licensed sterilisation facility. It does not remove the requirement for the sterilisation facility to hold a valid licence.
Concerns over sterilisation labelling remain
While the government has eased the licensing requirement, the medical-device industry has raised concerns about another part of the sterilisation framework.
Industry representatives have objected to requirements involving the licence number of an outsourced sterilisation facility being printed on product labels. They argue that such a requirement could reduce manufacturers' flexibility to switch between sterilisation providers and potentially create delays, particularly for exports.
The Association of Indian Medical Device Industry (AiMeD) has argued that manufacturers could face longer turnaround times if packaging is tied to a particular sterilisation subcontractor.
According to reporting by the Economic Times, AiMeD coordinator Rajiv Nath said the industry had sought a review of the labelling requirement, arguing that manufacturers should retain flexibility to select the fastest available licensed facility.
This creates an important distinction: the government has simplified the licensing process for outsourced sterilisation, but industry believes some related labelling requirements could still create operational difficulties.
A broader push to reform medical-device regulation
The latest measures form part of a wider effort by the Health Ministry to modernise India's medical-device regulatory system.
The government's stated objectives include reducing unnecessary regulatory burden, improving transparency, making costs more predictable and bringing advanced medical technologies to the Indian market more quickly.
The inclusion of the EU is especially significant because it expands the group of foreign regulatory jurisdictions whose approvals can support India's streamlined pathway.
For global medical-device companies, this could make India a more attractive market by reducing duplication in regulatory processes.
For Indian manufacturers, the standardisation of testing fees and easier access to licensed sterilisation facilities could reduce some of the operational hurdles involved in developing and marketing devices.
What it means for India's healthcare sector
If implemented effectively, the reforms could have effects beyond manufacturers.
Hospitals and doctors could gain earlier access to eligible advanced medical technologies. Patients could potentially benefit when newer diagnostic or treatment devices reach the Indian market sooner.
At the same time, faster access will depend on how regulators implement the amended rules and how quickly companies adapt their applications and compliance systems.
The reforms therefore represent an attempt to strike a balance: make the approval process faster and more predictable without compromising safety standards.
The road ahead
The government's latest amendments mark a significant shift toward greater reliance on trusted international regulatory systems and streamlined domestic procedures.
The EU's inclusion alongside the US, UK, Australia, Canada and Japan strengthens India's network of recognised stringent regulatory jurisdictions. The outsourced sterilisation amendment removes an additional licensing burden, while uniform testing fees seek to eliminate uncertainty over laboratory charges.
For patients, the most important potential outcome is straightforward: eligible advanced medical devices that have already cleared stringent regulatory scrutiny abroad may reach India sooner.
For the medical-device industry, the reforms could lower compliance costs and shorten regulatory timelines.
But the success of the changes will ultimately depend on implementation—and on whether the government can address industry concerns while preserving the safety and quality standards that underpin medical-device regulation.
Also Read: Rahul Gandhi Backs Kriti Sanon in Raksha Bandhan Ad Row